Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

HRTX

Heron Therapeutics Inc

Sep 12 • 04:00PM ET

1.26

-0.02 -1.56 %

Healthcare • Biotechnology • USA • NASD

Peers: JNJ PFE ABBV MRK BMY GILD LLY AMGN VRTX REGN

| Held by: VTI IWM VXF IWN VTWO SCHA VHT IWC ITOT IWO

Index	RUT	P/E	-	EPS (ttm)	-0.01	Insider Own	0.97%	Shs Outstand	153.25M	Perf Week	-3.82%
Market Cap	193.15M	Forward P/E	21.00	EPS next Y	0.06	Insider Trans	279.36%	Shs Float	151.81M	Perf Month	-10.00%
Enterprise Value	329.26M	PEG	-	EPS next Q	-0.01	Inst Own	88.73%	Short Float	21.33%	Perf Quarter	-37.31%
Income	-0.93M	P/S	1.29	EPS this Y	66.67%	Inst Trans	13.72%	Short Ratio	19.15	Perf Half Y	-45.69%
Sales	149.69M	P/B	-	EPS next Y	300.00%	ROA	-0.41%	Short Interest	32.39M	Perf YTD	-17.65%
Book/sh	-0.18	P/C	4.75	EPS next 5Y	-	ROE	-	52W High	2.68 -52.99%	Perf Year	-30.77%
Cash/sh	0.27	P/FCF	-	EPS past 3/5Y	65.87% 48.68%	ROIC	-	52W Low	1.04 21.15%	Perf 3Y	-71.75%
Dividend Est.	-	EV/EBITDA	87.57	Sales past 3/5Y	18.67% -0.23%	Gross Margin	74.61%	Volatility	3.95% 4.78%	Perf 5Y	-90.82%
Dividend TTM	-	EV/Sales	2.20	EPS Y/Y TTM	98.13%	Oper. Margin	0.96%	ATR (14)	0.08	Perf 10Y	-96.53%
Dividend Ex-Date	-	Quick Ratio	0.53	Sales Y/Y TTM	9.78%	Profit Margin	-0.62%	RSI (14)	31.91	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.82	EPS Q/Q	74.42%	SMA20	-4.98%	Beta	1.27	Target Price	4.75
Payout	-	Debt/Eq	-	Sales Q/Q	3.26%	SMA50	-23.35%	Rel Volume	0.83	Prev Close	1.28
Employees	122	LT Debt/Eq	-	Earnings	Aug 08 BMO	SMA200	-31.59%	Avg Volume	1.69M	Price	1.26
IPO	Aug 26, 1987	Option/Short	Yes / Yes	EPS/Sales Surpr.	-100.00% -2.30%	Trades		Volume	1,398,713	Change	-1.56%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-09-25	Initiated	H.C. Wainwright	Buy	$6
Jun-13-24	Initiated	Rodman & Renshaw	Buy	$7
Apr-23-24	Initiated	CapitalOne	Overweight	$6
Mar-13-24	Reiterated	Needham	Buy	$4 → $5
May-27-20	Initiated	Guggenheim	Buy	$24
Feb-20-20	Reiterated	Needham	Buy	$50 → $48
Jan-16-19	Reiterated	Needham	Buy	$66 → $64
Apr-05-18	Initiated	Evercore ISI	Outperform	$56
Mar-19-18	Reiterated	Mizuho	Buy	$28 → $35
Mar-01-18	Reiterated	Needham	Buy	$28 → $30
Jan-03-18	Initiated	Leerink Partners	Outperform	$22
Sep-27-17	Initiated	Northland Capital	Outperform	$40
Feb-27-17	Initiated	Needham	Buy	$28
Oct-26-16	Initiated	Aegis Capital	Buy
Sep-06-16	Resumed	Lake Street	Buy	$45
May-03-16	Initiated	Cantor Fitzgerald	Buy
Dec-10-15	Initiated	Lake Street	Buy	$45
Sep-23-15	Reiterated	Leerink Partners	Outperform	$38 → $57
Sep-02-15	Initiated	BofA/Merrill	Buy	$46
Aug-03-15	Reiterated	Brean Capital	Buy	$40 → $45

Show Previous Ratings

Aug-15-25 07:45AM	Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value (PR Newswire)
Aug-09-25 03:05AM	Heron Therapeutics Inc (HRTX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Aug-08-25 09:30AM	Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -28.26%
08:55AM	Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:52AM	Heron Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:45AM	Loading…
07:45AM	Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress (PR Newswire)
07:45AM	Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile (PR Newswire)
06:00AM	Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025 (PR Newswire)
Jul-28-25 09:42PM	Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025 (PR Newswire)
Jul-07-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Jul-04-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
May-07-25 03:38PM	Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025 (Seeking Alpha) -6.61%
03:04AM	Heron Therapeutics Inc (HRTX) Q1 2025 Earnings Call Highlights: Record EBITDA and Significant ... (GuruFocus.com)
May-06-25 09:30AM	Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics (Zacks) +13.62%
08:55AM	Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates (Zacks)
07:53AM	Loading…
07:53AM	Heron Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:45AM	Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
07:30AM	Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI and APONVIE Patent Litigations (PR Newswire)
May-05-25 10:33AM	MTD Q1 Earnings Top Estimates, Sales Decline Y/Y, Shares Rise (Zacks) -7.79%
May-01-25 10:01AM	Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-29-25 10:01AM	Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-28-25 06:55PM	Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer (PR Newswire)
Apr-24-25 08:56AM	Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics (Zacks)
Apr-23-25 09:32AM	5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Apr-22-25 04:05PM	Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025 (PR Newswire) +11.40%
10:15AM	Best Momentum Stocks to Buy for April 22nd (Zacks)
09:40AM	Are Medical Stocks Lagging Encompass Health (EHC) This Year? (Zacks)
07:24AM	New Strong Buy Stocks for April 22nd (Zacks)
Mar-26-25 03:57PM	Is Heron Therapeutics, Inc. (HRTX) The Hot Biotech Stock Under $5? (InsiderMonkey)
02:08AM	Loading…
Feb-28-25 02:08AM	Heron Therapeutics Inc (HRTX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) +20.49%
12:56AM	Q4 2024 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-25 09:30AM	Heron Therapeutics (HRTX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +19.88%
07:54AM	Heron Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:45AM	Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Feb-13-25 04:20PM	Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025 (PR Newswire) +7.88%
Dec-23-24 04:05PM	Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina (PR Newswire)
Dec-03-24 04:36PM	U.S. District Court Upholds Validity of CINVANTI Patents (PR Newswire) +38.98%
Nov-13-24 02:05AM	Heron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights (GuruFocus.com) -5.47%
Nov-12-24 10:00AM	Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks) -30.43%
09:10AM	Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:06AM	Heron Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:55AM	Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance (PR Newswire)
Nov-07-24 09:15AM	Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Nov-04-24 05:00PM	Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors (PR Newswire)
Oct-29-24 04:05PM	Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024 (PR Newswire) -7.33%
Oct-10-24 04:08PM	Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI, SUSTOL, and APONVIE as Alternatives During the Potential Shortage of Intravenous Fluids (PR Newswire)
Sep-25-24 08:00AM	Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF Vial Access Needle ('VAN') (PR Newswire)
Sep-03-24 08:00AM	Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer (PR Newswire) -10.36%
Aug-06-24 07:30PM	Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -25.09%
06:45PM	Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:36PM	Heron Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance (PR Newswire)
Jul-30-24 04:05PM	Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 (PR Newswire) +5.69%
Jul-15-24 08:00AM	Heron Therapeutics Announces the Inclusion of ZYNRELEF as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System (PR Newswire)
Jul-11-24 12:00PM	Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +8.88%
Jul-02-24 08:00AM	Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF Vial Access Needle ('VAN') (PR Newswire) -21.04%
May-29-24 08:05AM	Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF Vial Access Needle ('VAN') (PR Newswire)
May-21-24 12:00PM	What Makes Heron Therapeutics (HRTX) a Strong Momentum Stock: Buy Now? (Zacks)
May-08-24 12:30PM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:10AM	Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Call Transcript Highlights: Significant ... (GuruFocus.com)
May-07-24 12:54PM	HRTX Stock Earnings: Heron Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:34AM	Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Overview: Surpasses Revenue Estimates (GuruFocus.com)
09:30AM	Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
09:05AM	Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:06AM	Heron Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Apr-30-24 10:01AM	Will Heron Therapeutics (HRTX) Report Negative Earnings Next Week? What You Should Know (Zacks) -7.20%
Apr-24-24 08:00AM	Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 (PR Newswire) -5.36%
Apr-11-24 04:05PM	Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City (PR Newswire) +7.69%
Mar-28-24 04:05PM	Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-13-24 09:19AM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2023 Earnings Call Transcript (Insider Monkey) +27.54%
07:04AM	Q4 2023 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-12-24 06:00PM	Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key Metrics (Zacks)
05:33PM	Heron Therapeutics Inc (HRTX) Exceeds Full-Year Revenue Guidance for 2023 (GuruFocus.com)
04:34PM	Heron Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Mar-07-24 09:15AM	Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Feb-28-24 08:00AM	Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024 (PR Newswire)
Feb-23-24 11:56AM	12 Best Rising Penny Stocks To Buy (Insider Monkey)
Feb-06-24 12:00PM	All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Strong Buy (Zacks)
Jan-25-24 06:44AM	Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion (Zacks)
Jan-24-24 01:47PM	Heron Therapeutics' Non-Opioid, Post-Operative Pain Drug Approved For Use In Additional Orthopedic, Soft Tissue Procedures - FDA Gives Nod (Benzinga) +18.86%
Jan-23-24 08:00PM	Heron Therapeutics Announces FDA Approval of ZYNRELEF Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures (PR Newswire) -5.98%
Jan-15-24 04:51PM	The 3 Most Undervalued Biotech Stocks to Buy in January (InvestorPlace)
09:55AM	Heron Therapeutics (HRTX) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Jan-07-24 05:00PM	Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain (PR Newswire)
Dec-10-23 12:23PM	Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master (Associated Press Finance)
Dec-06-23 11:55AM	13 Hot Penny Stocks To Buy According to Hedge Funds (Insider Monkey)
Nov-28-23 07:33PM	Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth (InvestorPlace) -7.95% +7.00%
Nov-15-23 10:17AM	Heron Therapeutics Inc (HRTX) Raises 2023 Sales Guidance and Projects Positive EBITDA in 2024 (GuruFocus.com) +59.26%
08:51AM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2023 Earnings Call Transcript (Insider Monkey)
08:46AM	Q3 2023 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-14-23 06:00PM	Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
04:17PM	Heron Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance (PR Newswire)
Nov-07-23 04:05PM	Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023 (PR Newswire) +6.88% -9.20%
Aug-24-23 09:29AM	11 Best Long-Term Penny Stocks to Buy Now (Insider Monkey)
Aug-15-23 01:30PM	Heron Therapeutics (HRTX) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) +10.93%
12:48PM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2023 Earnings Call Transcript (Insider Monkey)

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in Cary, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rubric Capital Management LP	10% Owner	Aug 08 '25	Buy	1.50	2,387,225	3,580,838	29,100,728	Aug 12 06:00 PM
Morgan Adam	Director	Aug 08 '25	Buy	1.50	1,766,546	2,649,819	8,753,290	Aug 12 05:02 PM

Open in Screener

GOSS

Gossamer Bio Inc

Sep 12 • 04:00PM ET

3.46

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Peers: BLUE CRSP SRPT FATE NTLA ADAP EDIT QURE BMRN VYGR

| Held by: IWM VTI IWO VXF SCHA VTWO IWC ITOT SBIO SCHB

Index	RUT	P/E	-	EPS (ttm)	-0.61	Insider Own	19.65%	Shs Outstand	227.32M	Perf Week	17.69%
Market Cap	786.73M	Forward P/E	-	EPS next Y	-0.47	Insider Trans	0.06%	Shs Float	182.70M	Perf Month	75.63%
Enterprise Value	776.64M	PEG	-	EPS next Q	-0.19	Inst Own	61.54%	Short Float	12.07%	Perf Quarter	172.44%
Income	-138.74M	P/S	19.55	EPS this Y	-167.09%	Inst Trans	5.40%	Short Ratio	6.48	Perf Half Y	166.15%
Sales	40.24M	P/B	-	EPS next Y	29.29%	ROA	-45.17%	Short Interest	22.05M	Perf YTD	282.49%
Book/sh	-0.20	P/C	3.69	EPS next 5Y	6.00%	ROE	-783.37%	52W High	3.50 -1.14%	Perf Year	275.88%
Cash/sh	0.94	P/FCF	-	EPS past 3/5Y	56.92% 40.29%	ROIC	-89.03%	52W Low	0.66 422.90%	Perf 3Y	-76.33%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	93.26%	Volatility	11.23% 8.80%	Perf 5Y	-73.12%
Dividend TTM	-	EV/Sales	19.30	EPS Y/Y TTM	-57.23%	Oper. Margin	-361.91%	ATR (14)	0.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.40	Sales Y/Y TTM	-58.02%	Profit Margin	-344.81%	RSI (14)	76.97	Recom	1.22
Dividend Gr. 3/5Y	- -	Current Ratio	4.40	EPS Q/Q	-181.59%	SMA20	36.68%	Beta	1.97	Target Price	8.86
Payout	-	Debt/Eq	-	Sales Q/Q	-88.01%	SMA50	68.05%	Rel Volume	1.25	Prev Close	3.46
Employees	145	LT Debt/Eq	-	Earnings	Aug 05 AMC	SMA200	163.18%	Avg Volume	3.40M	Price	3.46
IPO	Feb 08, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.01% 112.41%	Trades		Volume	4,235,061	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-10-25	Upgrade	UBS	Neutral → Buy	$9
Jul-14-25	Initiated	Scotiabank	Sector Outperform	$11
Jun-25-24	Initiated	Oppenheimer	Outperform	$9
Apr-05-24	Resumed	Wedbush	Outperform	$4
Jul-27-23	Downgrade	UBS	Buy → Neutral	$8 → $1.25
Mar-07-23	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-23	Initiated	Guggenheim	Neutral
Dec-07-22	Downgrade	SMBC Nikko	Outperform → Neutral	$3
Dec-07-22	Downgrade	JP Morgan	Neutral → Underweight
Dec-07-22	Downgrade	Barclays	Overweight → Equal Weight	$18 → $2
Oct-20-22	Initiated	Goldman	Buy	$22
Sep-21-22	Initiated	JP Morgan	Neutral	$17
Sep-19-22	Initiated	Wedbush	Outperform	$24
Apr-18-22	Initiated	Raymond James	Outperform	$19
Apr-06-22	Initiated	UBS	Buy	$19
Jan-10-22	Upgrade	SMBC Nikko	Neutral → Outperform	$24
Nov-09-21	Resumed	Cantor Fitzgerald	Overweight	$20
Sep-21-21	Resumed	Piper Sandler	Overweight	$26
Jun-29-20	Initiated	H.C. Wainwright	Buy	$31
Apr-22-20	Initiated	Piper Sandler	Overweight	$30

Show Previous Ratings

Sep-11-25 01:15PM	H.C. Wainwright Asserts Buy Stance on Gossamer Bio Inc. (GOSS) on Pulmonary Arterial Hypertension Drug Prospects (Insider Monkey) +11.25%
03:31AM	Piper Sandler Reiterates Buy as Seralutinib Momentum Boosts Gossamer (GOSS) Multibagger Case (Insider Monkey)
Sep-10-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +12.27%
Aug-29-25 07:31AM	Gossamer Bio to Present at Upcoming Investor Conferences (Business Wire)
Aug-19-25 12:06AM	H.C. Wainwright and Leerink Partners Reiterate 'Buy' Ratings on Gossamer Bio, Inc. (GOSS) (Insider Monkey)
05:30PM	Loading…
Aug-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -12.12%
Aug-05-25 05:55PM	Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -8.33%
04:53PM	Gossamer Bio: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
08:40AM	Harmony Biosciences Holdings, Inc. (HRMY) Misses Q2 Earnings and Revenue Estimates (Zacks)
Jul-30-25 07:05AM	GSK (GSK) Q2 Earnings and Revenues Beat Estimates (Zacks) +6.12%
Jun-24-25 12:46PM	Gossamer Bio Completes Enrollment for Phase 3 PROSERA Study of PAH Drug Seralutinib (Insider Monkey)
Jun-16-25 07:31AM	Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH (Business Wire)
Jun-06-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.56%
May-21-25 07:00AM	Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream (GlobeNewswire)
09:11AM	Loading…
May-16-25 09:11AM	Q1 2025 Gossamer Bio Inc Earnings Call (Thomson Reuters StreetEvents)
03:15AM	Gossamer Bio Inc (GOSS) Q1 2025 Earnings Call Highlights: Strategic Progress Amid Financial ... (GuruFocus.com)
May-15-25 05:15PM	Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:09PM	Gossamer Bio: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study (Business Wire)
May-14-25 09:45AM	What To Expect From Gossamer Bio Inc (GOSS) Q1 2025 Earnings (GuruFocus.com) -7.34%
May-12-25 04:01PM	Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025 (Business Wire)
May-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:01PM	Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference (Business Wire)
May-02-25 01:21PM	Gossamer Bio: Initiating Hold As Late-Stage Data Nears Inflection (Seeking Alpha) +11.32%
Apr-16-25 09:57AM	Is Gossamer Bio Inc. (NASDAQ:GOSS) the Best Penny Stock to Invest in Under $1? (Insider Monkey)
Apr-09-25 09:44AM	Gossamer Bio, Inc. (GOSS): Among Stocks Under $10 that Will Triple (Insider Monkey) +11.76%
Apr-08-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-27-25 09:45AM	Is Gossamer Bio Inc. (GOSS) the Popular Penny Stock on Robinhood to Watch? (InsiderMonkey)
Mar-26-25 01:38PM	Is Gossamer Bio, Inc. (GOSS) The Hot Biotech Stock Under $5? (InsiderMonkey) -7.81%
08:41AM	Loading…
Mar-23-25 08:41AM	Gossamer Bio (GOSS): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-13-25 05:10PM	Gossamer Bio (GOSS) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +11.54%
04:06PM	Gossamer Bio: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update (Business Wire)
Mar-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-19-25 06:00AM	Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now (GlobeNewswire)
Feb-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +10.38%
Feb-03-25 07:01AM	Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress (Business Wire)
Jan-28-25 07:01AM	Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress (Business Wire)
Jan-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.41%
09:19AM	Why Gossamer Bio, Inc. (GOSS) Is Among the Best Penny Stocks to Invest In According to Media? (Insider Monkey)
Dec-26-24 12:00PM	Gossamer Bio (GOSS) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-21-24 12:00PM	All You Need to Know About Gossamer Bio (GOSS) Rating Upgrade to Buy (Zacks)
Nov-15-24 09:35AM	After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) (Zacks)
Nov-14-24 09:35AM	After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) (Zacks) -5.59%
Nov-11-24 04:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-24 06:00PM	Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:59PM	Gossamer Bio: Q3 Earnings Snapshot (Associated Press Finance)
04:03PM	Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Oct-31-24 07:00AM	NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule (GlobeNewswire)
Oct-30-24 07:00AM	Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now (GlobeNewswire)
Oct-29-24 07:00AM	Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now (GlobeNewswire)
Oct-07-24 05:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-25-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 2 on September 26 (GlobeNewswire)
Sep-24-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now (GlobeNewswire)
Aug-26-24 04:01PM	Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024 (Business Wire)
Aug-21-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now (GlobeNewswire)
Aug-20-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now (GlobeNewswire)
Aug-12-24 10:53PM	GOSS Stock Earnings: Gossamer Bio Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace)
05:10PM	Gossamer Bio (GOSS) Q2 Earnings and Revenues Lag Estimates (Zacks)
04:15PM	Gossamer Bio: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-25-24 02:35AM	Why Is Gossamer Bio, Inc. (GOSS) the Best One-Dollar Stock to Buy Now? (Insider Monkey)
Jun-13-24 03:35PM	The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street (InvestorPlace)
Jun-07-24 04:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.60% -6.09%
May-14-24 04:01PM	Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference (Business Wire)
May-10-24 04:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-07-24 10:56PM	GOSS Stock Earnings: Gossamer Bio Misses EPS for Q1 2024 (InvestorPlace) -6.30%
05:15PM	Gossamer Bio: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
05:11AM	Gossamer Bio and Chiesi partner for pulmonary hypertension treatment (Pharmaceutical Technology)
04:31AM	Gossamer Bio and Chiesi link for pulmonary hypertension treatment (Pharmaceutical Technology)
May-06-24 03:17PM	Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide (Benzinga) +5.50%
08:17AM	UPDATE 1-Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition (Reuters)
08:11AM	Gossamer sells rights to drug it hopes can rival a new Merck therapy (BioPharma Dive)
07:41AM	Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment (Reuters)
07:30AM	Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications (Business Wire)
May-03-24 08:02AM	Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine (Business Wire)
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Mar-12-24 07:31AM	Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors (Business Wire)
Mar-07-24 09:55AM	Should You Buy Gossamer Bio (GOSS) After Golden Cross? (Zacks) -7.95%
Mar-05-24 10:52PM	GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023 (InvestorPlace)
07:55AM	Gossamer Bio Posts Narrower Loss In Q4 - Quick Facts (RTT News)
07:40AM	Gossamer Bio: Q4 Earnings Snapshot (Associated Press Finance)
07:31AM	Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update (Business Wire)
Feb-27-24 03:30AM	12 Best Medical Stocks to Buy Under $10 (Insider Monkey)
Jan-31-24 02:23PM	7 Micro-Cap Stocks That Could Majorly Surprise Investors (InvestorPlace)
Jan-22-24 10:53AM	5 Small-Cap Stocks with High Potential (Insider Monkey)
Jan-08-24 04:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.24% +7.16%
Dec-13-23 04:01PM	Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023 (Business Wire)
Dec-05-23 04:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.31%
07:01AM	Gossamer Bio Appoints Bob Smith as Chief Commercial Officer (Business Wire)
Nov-29-23 07:01AM	Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors (Business Wire)
Nov-09-23 08:11AM	Gossamer Bio Inc (GOSS) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com) -7.56%
07:41AM	Gossamer Bio: Q3 Earnings Snapshot (Associated Press Finance)
07:31AM	Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Oct-23-23 10:08AM	12 Best Penny Stocks to Buy Under $1 (Insider Monkey) -6.46%
Oct-03-23 04:08PM	Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs (Business Wire) -5.57%
Sep-07-23 07:44AM	Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023 (Business Wire)
Aug-28-23 08:20AM	TENX: Second Quarter Results (Zacks)

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 26, 2015 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Milligan Sandra	Director	Aug 19 '25	Buy	1.92	26,050	50,016	58,050	Aug 20 04:04 PM

HRTX

Heron Therapeutics Inc

GOSS

Gossamer Bio Inc

Upgrade your FINVIZ experience